BioCrossroads Invests in Innovative Biotech Targeting Challenging Diseases

INDIANAPOLIS, Dec. 23, 2010 /PRNewswire/ — BioCrossroads’ Indiana Seed Fund has
announced its eleventh investment, committing $250,000 to biotech start-up
Aarden Pharmaceuticals. Based in Indianapolis but drawing key parts of its
veteran entrepreneurial team from San Diego, Aarden is developing novel
technologies to attack difficult-to-treat diseases through focus on specific
intracellular disease targets. The BioCrossroads investment will support the
company to advance its lead program, a tuberculosis (TB) treatment, through the
pre-clinical development stage.

Aarden’s scientific platform comes through the work of Dr. Zhong-Yin Zhang,
Robert A. Harris Professor and Chairman of Biochemistry and Molecular Biology at
Indiana University School of Medicine, and an internationally recognized expert
in the field of protein tyrosine phosphatases (PTPs), a large family of
signaling enzymes that regulate a wide array of essential cellular processes.
Dr. Zhang’s work is based on novel chemistry that allows drugs to work more
effectively in finding their targets.

“Aarden’s research was born in Dr. Zhang’s laboratory, which was funded through
Lilly Endowment’s historic Indiana Genomics Initiative (INGEN) grant to the
Indiana University School of Medicine several years ago,” said David Johnson,
president and CEO of BioCrossroads. “The goal of INGEN was to make Indiana a
destination point for 21st century biotechnology discovery and, in so doing,
bring more translational research to life for better human health. Aarden’s
promising science, pre-eminent research and outstanding leadership team
illustrate very well the full promise of the grant.”

The second leading cause of death in the world, approximately 2 million people
die from tuberculosis each year. Current treatments are insufficient. Often,
existing antibiotics are not fully effective, particularly against multi-drug
resistant TB under a regimen that demands arduous treatments for up to nine
months. Aarden’s drug has the potential to address current challenges – offering
a shorter treatment duration and a stronger, more efficacious treatment.

Along with its TB therapeutic platform, Aarden is also making progress in
research efforts in cancer (e.g. leukemia) and autoimmune diseases (e.g.
rheumatoid arthritis and lupus). The company’s cancer and autoimmune programs
are currently in pre-clinical testing.

“BioCrossroads’ continuing support has value even beyond this important
financial commitment. Certainly, this investment from the BioCrossroads Seed
Fund will help us accelerate the progress of our TB program,” said Aarden CEO
Gary Noonan. “It’s a testament to our science and team that we are now part of
the group of high caliber start ups that BioCrossroads has funded.”

About BioCrossroads

BioCrossroads (www.biocrossroads.com) is Indiana’s initiative to grow, advance
and invest in the life sciences, a publicprivate collaboration that supports the
region’s existing research and corporate strengths while encouraging new
business development. BioCrossroads provides money and support to life sciences
businesses, launches new life sciences enterprises (Indiana Health Information
Exchange, Fairbanks Institute for Healthy Communities, BioCrossroadsLINX, and
Datalys Center), expands collaboration and partnerships among Indiana’s life
science institutions, promotes science education and markets Indiana’s life
sciences industry.

About the Indiana Seed Fund I

The $6 million, returndriven Indiana Seed Fund was launched in June 2005 and is
managed by BioCrossroads with funding from BioCrossroads, the Indiana Finance
Authority and the Indiana Economic Development Corporation. The Seed Fund
provides working capital in the range of $50,000$500,000 to promising Indiana
life sciences companies at the preliminary stages of operation.

About Aarden

Aarden (www.aardenpharma.com) is a small molecule drug discovery and development
company. The company’s novel technology from the labs of the Indiana University
School of Medicine is a chemistry breakthrough that will enable it to make drugs
against a previously undruggable set of intracellular phosphatase (PTP) disease
targets. Aarden’s first programs are focused on infectious disease, cancer,
metabolic and autoimmune conditions.

SOURCE BioCrossroads